Royalty Pharma (NASDAQ:RPRX) EVP Sells $4,374,700.00 in Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP George Lloyd sold 110,000 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $39.77, for a total value of $4,374,700.00. Following the transaction, the executive vice president directly owned 110,000 shares in the company, valued at approximately $4,374,700. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Royalty Pharma Trading Up 1.5%

NASDAQ RPRX traded up $0.58 during trading hours on Friday, hitting $39.73. 10,236,174 shares of the company’s stock were exchanged, compared to its average volume of 4,300,432. The business’s 50 day moving average is $37.77 and its 200-day moving average is $36.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. Royalty Pharma PLC has a 12-month low of $24.05 and a 12-month high of $41.24. The firm has a market capitalization of $22.93 billion, a P/E ratio of 30.10, a price-to-earnings-growth ratio of 2.09 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.06. The company had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. As a group, analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a $0.22 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $0.88 annualized dividend and a dividend yield of 2.2%. Royalty Pharma’s payout ratio is presently 66.67%.

Institutional Investors Weigh In On Royalty Pharma

Several large investors have recently modified their holdings of the stock. Smartleaf Asset Management LLC increased its stake in shares of Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 790 shares in the last quarter. USA Financial Formulas bought a new position in shares of Royalty Pharma in the 2nd quarter worth $32,000. Financial Consulate Inc. acquired a new position in shares of Royalty Pharma during the 3rd quarter worth about $35,000. Summit Securities Group LLC acquired a new position in Royalty Pharma during the first quarter valued at approximately $36,000. Finally, WPG Advisers LLC bought a new stake in shares of Royalty Pharma in the 1st quarter valued at $39,000. 54.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

RPRX has been the subject of a number of analyst reports. Weiss Ratings lowered Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. Wall Street Zen cut shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 28th. TD Cowen downgraded Royalty Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 17th. Morgan Stanley decreased their target price on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Finally, The Goldman Sachs Group assumed coverage on Royalty Pharma in a report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price target on the stock. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Royalty Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $46.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.